Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Marie José Kersten, MD PhD, Monique C. Minnema, Josephine M. Vos, MD PhD, Kazem Nasserinejad, Marcel Kap, BSc, Eftathios Kastritis, Maria Gavriatopoulou, MD, Martine E.D. Chamuleau, Dries Deeren, MD PhD, Lidwine Winnifred Tick, MD PhD, Jeanette K. Doorduijn, MD PhD, Fritz Offner, MD, Lara H Bohmer, MD, Karima Amaador, MD, Roberto D Liu, BSc, Steven T Pals, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 344.

https://doi.org/10.1182/blood-2019-122365

Published: 2019

Journal Articles

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Blood (2019) 134 (Supplement_1): 3195.

https://doi.org/10.1182/blood-2019-124388

Published: 2019

Journal Articles

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Blood (2018) 132 (Supplement 1): 301.

https://doi.org/10.1182/blood-2018-99-112079

Published: 2018

Journal Articles

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Blood (2018) 132 (Supplement 1): 1959.

https://doi.org/10.1182/blood-2018-99-112046

Published: 2018

Journal Articles

Safety of Direct Oral Anticoagulants in Patients with Cirrhosis: A Systematic Review and Meta-Analysis

Kamolyut Lapumnuaypol, MD, Thita Chiasakul, MD MSc

Blood (2018) 132 (Supplement 1): 1238.

https://doi.org/10.1182/blood-2018-99-117255

Published: 2018

Journal Articles

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

John Peterson, PhD, Myung-Gi Baek, PhD, Silvia Locatelli-Hoops, PhD, Ji-Won Lee, PhD, Lingquan Deng, PhD, David A Stewart, Theodore AG Smith, PhD, Daniel Durant Myers, DVM, MPH, William E Fogler, PhD, John L Magnani, PhD

Blood (2018) 132 (Supplement 1): 4678.

https://doi.org/10.1182/blood-2018-99-116779

Published: 2018

Journal Articles

Absence of Vasoactive Intestinal Peptide Synthesis in Recipients in Allogeneic Bone Marrow Transplant Increases Graft Versus Host Diseases

Yiwen Li, BS, MMSc, Jianming Li, PhD, Yitong Wang, MD, Edmund K. Waller, MD

Blood (2017) 130 (Supplement 1): 4437.

https://doi.org/10.1182/blood.V130.Suppl_1.4437.4437

Published: 2017

Journal Articles

Iron Supplementation: What's New?

Iain C. Macdougall, MD

Blood (2017) 130 (Supplement 1): SCI-43.

https://doi.org/10.1182/blood.V130.Suppl_1.SCI-43.SCI-43

Published: 2017

Journal Articles

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Meletios A. Dimopoulos, Jacob Laubach, MD, Maria Asuncion Echeveste Gutierrez, Norbert Grząśko, Craig C Hofmeister, MDMPH, Jesus F. San Miguel, MD, Shaji K Kumar, MD, Vickie Lu, PhD, Zhaoyang Teng, PhD, Guohui Liu, PhD, Catriona Byrne, RN, Deborah Berg, RN, MSN, Richard Labotka, MD MS, Helgi van de Velde, MD PhD, Paul G Richardson, MD

Blood (2017) 130 (Supplement 1): 902.

https://doi.org/10.1182/blood.V130.Suppl_1.902.902

Published: 2017

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Jacqueline ML Halton, MD, Anne-Caroline Picard, Ruth Harper, Fenglei Huang, Martina Brueckmann, MD, Savion Gropper, MD, Hugo Maas, Igor Tartakovsky, MD, Ildar Nurmeev, Lesley G Mitchell, Leonardo R. Brandão, MD MSc, Manuela Albisetti, MD

Blood (2016) 128 (22): 1441.

https://doi.org/10.1182/blood.V128.22.1441.1441

Published: 2016

Journal Articles

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Manuela Albisetti, MD, Ivan Manastirski, Martina Brueckmann, MD, Savion Gropper, MD, Bushi Wang, Igor Tartakovsky, MD, Branislav Biss, Fenglei Huang, Lesley G Mitchell, MSc, Leonardo R. Brandão, MD MSc, Jacqueline ML Halton, MD

Blood (2016) 128 (22): 5025.

https://doi.org/10.1182/blood.V128.22.5025.5025

Published: 2016

Journal Articles

Effectiveness and Safety of Rivaroxaban in Treatment of Venous Thromboembolism in Cancer Patients

Khine Z Win, MD, Nathan Wilson, PharmD, David D Stenehjem, PharmD, Natalee Tanner, PharmD, George M. Rodgers, MD PhD, Jeffrey Gilreath, PharmD

Blood (2015) 126 (23): 2319.

https://doi.org/10.1182/blood.V126.23.2319.2319

Published: 2015

Journal Articles

Characteristics and Treatment Patterns of Patients with Deep Vein Thrombosis and/or Pulmonary Embolism in the US Hospital Setting

Matthew Sussman, Jonathan Lim, Cheng Wang, Mark Friedman, MD, Stephen Sander, Robert Griffiths

Blood (2015) 126 (23): 2061.

https://doi.org/10.1182/blood.V126.23.2061.2061

Published: 2015

Journal Articles

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

Shaji K Kumar, MD, Vivek Roy, M.D., Craig Reeder, MD, Betsy R. LaPlant, Martha Q Lacy, MD, Morie A Gertz, MD, MACP, Kristina Laumann, Melanie Ann Thompson, Thomas E Witzig, MD, Francis K Buadi, MD, Candido E. Rivera, MD, Joseph R. Mikhael, MD, Peter Leif Bergsagel, MD, Lisa Hwa, RN, CNP, S. Vincent Rajkumar, MD, Angela Dispenzieri, MD

Blood (2013) 122 (21): 1944.

https://doi.org/10.1182/blood.V122.21.1944.1944

Published: 2013

Journal Articles

Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727

Aram Oganesian, PhD, Sanjeev Redkar, PhD, Pietro Taverna, PhD, Rajashree Joshi-Hangal, PhD, Mohammad Azab, MD

Blood (2013) 122 (21): 2526.

https://doi.org/10.1182/blood.V122.21.2526.2526

Published: 2013

Journal Articles

Oral Administration Of a BMP Type I Receptor Inhibitor Prevents The Development Of Anemia Of Inflammation

Claire Mayeur, MD, Starsha A Kolodziej, Amy Wang, Xin Xu, Arthur Lee, Paul B. Yu, MD, PhD, John Shen, PhD, Kenneth D. Bloch, MD

Blood (2013) 122 (21): 2195.

https://doi.org/10.1182/blood.V122.21.2195.2195

Published: 2013

Journal Articles

Upregulation Of Hepcidin Expression By Lactoferrin Administration To Pre-Weanling Mice

Memisoglu Elif, BS, Jeffrey A. Cooper, MD, Robert E. Fleming, MD

Blood (2013) 122 (21): 964.

https://doi.org/10.1182/blood.V122.21.964.964

Published: 2013

Journal Articles

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

Mohsen Saleh Elalfy, Yasser Wali, MD, FRCPCH, (UK), S Tony, Ahmed Samir, Amira Adly

Blood (2013) 122 (21): 559.

https://doi.org/10.1182/blood.V122.21.559.559

Published: 2013

Journal Articles

The Efficacy and Safety of Pharmacological Prophylaxis of VTE Following Elective Knee or Hip Replacement: Systematic Review and Network Meta-Analysis

Ander Cohen, Drost Pieter, Nick Marchant, Stephen Mitchell, Michelle Orme, Teresa Simon, Alex Sutton, Dale Rublee

Blood (2011) 118 (21): 2314.

https://doi.org/10.1182/blood.V118.21.2314.2314

Published: 2011

Journal Articles

Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release

Ruei-Zeng Lin, Alexandra Dreyzin, Kristie Aamodt, Dan Li, Shou-Ching S. Jaminet, Andrew C. Dudley, Juan M. Melero-Martin

Blood (2011) 118 (20): 5420–5428.

https://doi.org/10.1182/blood-2011-08-372946

Published: 2011

Includes: Supplemental data

NARROW

Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial

Efficacy and Safety of Ixazomib-Dexamethasone, Ixazomib-Cyclophosphamide-Dexamethasone, Ixazomib-Thalidomide-Dexamethasone and Ixazomib-Bendamustine-Dexamethasone for Elderly Newly Diagnosed Multiple Myeloma (NDMM) Patients: Analysis of the Phase II Randomized Unito-EMN10 Study

Maintenance Therapy with the Oral Proteasome Inhibitor (PI) Ixazomib Significantly Prolongs Progression-Free Survival (PFS) Following Autologous Stem Cell Transplantation (ASCT) in Patients with Newly Diagnosed Multiple Myeloma (NDMM): Phase 3 Tourmaline-MM3 Trial

Treatment of Relapsed and Refractory Multiple Myeloma with Fully Oral Triplet IRD (ixazomib, lenalidomide and dexamethasone) Is Safe and with Significant Therapeutic Outcomes

Safety of Direct Oral Anticoagulants in Patients with Cirrhosis: A Systematic Review and Meta-Analysis

A Novel and Potent Inhibitor of E-Selectin, GMI-1687, Attenuates Thrombus Formation and Augments Chemotherapeutic Intervention of AML in Preclinical Models Following Subcutaneous Administration

Absence of Vasoactive Intestinal Peptide Synthesis in Recipients in Allogeneic Bone Marrow Transplant Increases Graft Versus Host Diseases

Iron Supplementation: What's New?

Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies

Pharmacokinetics (PK) and Pharmacodynamics (PD), Safety and Tolerability of a Single-Dose Oral Solution of Dabigatran Etexilate Given after Standard Anticoagulant Therapy in Children from Birth to Less Than One Year Old, with Venous Thromboembolism

Rationale and Design of a Phase IIb/III Open-Label, Multicenter Study of Dabigatran Etexilate for Venous Thromboembolism in Children: The Diversity Study

Effectiveness and Safety of Rivaroxaban in Treatment of Venous Thromboembolism in Cancer Patients

Characteristics and Treatment Patterns of Patients with Deep Vein Thrombosis and/or Pulmonary Embolism in the US Hospital Setting

Phase 2 Trial Of Single Agent MLN9708 In Patients With Relapsed Multiple Myeloma Not Refractory To Bortezomib

Preclinical Data In Cynomolgus (cyn) Monkeys Of ASTX727, a Novel Oral Hypomethylating Agent (HMA) Composed Of Low-Dose Oral Decitabine Combined With a Novel Cytidine Deaminase Inhibitor (CDAi) E7727

Oral Administration Of a BMP Type I Receptor Inhibitor Prevents The Development Of Anemia Of Inflammation

Upregulation Of Hepcidin Expression By Lactoferrin Administration To Pre-Weanling Mice

Comparison Of Two Combination Iron Chelation Regimens, Deferiprone and Deferasirox Versus Deferiprone and Deferoxamine, In Pediatric Patients With β-Thalassemia Major

The Efficacy and Safety of Pharmacological Prophylaxis of VTE Following Elective Knee or Hip Replacement: Systematic Review and Network Meta-Analysis

Induction of erythropoiesis using human vascular networks genetically engineered for controlled erythropoietin release

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only